Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 hour 11 min ago

Hansen Medical Announces Expanded Protocol for the ARTISAN AF IDE Study

Thu, 02/05/2015 - 15:41
FDA Approves Inclusion of the Latest Technology for the Treatment of Atrial Fibrillation MOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced FDA appr...
Devices, Cardiology, FDA
Hansen Medical, Sensei, Robotic Catheter, atrial fibrillation

First TomoTherapy(R) System in Latin America Dedicated Solely to Breast Cancer Care Now Treating Patients

Wed, 02/04/2015 - 13:50
Advanced Radiation Therapy System Ideally Suited for Efficient, Effective Treatment of Range of Breast Cancer Cases SUNNYVALE, Calif., Feb. 4, 2015 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today that the first ...
Devices, Radiology, Oncology
Accuray, TomoTherapy, radiotherapy, IMRT, TomoHelical

Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases

Wed, 02/04/2015 - 13:44
Company Secures Exclusive License Agreement with University of Illinois SAN FRANCISCO/REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--Third Rock Ventures, LLC today announced the formation of REVOLUTION Medicines, Inc. with a $45 million S...
Biopharmaceuticals, Venture Capital

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

Wed, 02/04/2015 - 13:38
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Concert Pharmaceuticals, Inc. (CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert’s product...
Biopharmaceuticals, Personnel
Concert Pharmaceuticals

Mazor Robotics Names Sandra Adzic Vice President of International Sales

Wed, 02/04/2015 - 13:32
CAESAREA, Israel--(Healthcare Sales & Marketing Network)--Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a developer of innovative guidance systems and complementary products, today announced that Sandra Adzic has been named Vice President of Internationa...
Devices, Surgery, Personnel
Mazor Robotics, Renaissance, robotic surgery

Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

Wed, 02/04/2015 - 13:23
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III GADOLIN study, which evaluated treatment options for people with i...
Biopharmaceuticals, Oncology
Genentech, Roche Group, GADOLIN study, Gazyva, obinutuzumab

SpineGuard Receives FDA Clearance to Market Its PediGuard Products for Minimally Invasive Surgery (MIS)

Tue, 02/03/2015 - 20:31
PARIS & SAN FRANCISCO--(Healthcare Sales & Marketing Network)--SpineGuard (FR0011464452 – ALSGD) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its PediGuard products for Minimally Invasive ...
Devices, Orthopaedic, Neurosurgery, FDA
SpineGuard, PediGuard, pedicle screw

Guardant Health Secures Additional $50 Million Based On Strong Demand For Its Biopsy-Free Cancer Blood Test, Guardant360(R)

Tue, 02/03/2015 - 13:32
The enhanced Guardant360 now identifies all classes of actionable tumor genomic alterations with a single blood test REDWOOD CITY, Calif., Feb. 3, 2015 -- (Healthcare Sales & Marketing Network) -- Guardant Health today announced the completion of its S...
Diagnostics, Oncology, Venture Capital
Guardant Health, Guardant360, biopsy-free cancer test, liquid biopsy

U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

Tue, 02/03/2015 - 13:21
RARITAN, N.J., Feb. 3, 2015 -- (Healthcare Sales & Marketing Network) -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YOND...
Biopharmaceuticals, Oncology
Janssen Research & Development, YONDELIS, trabectedin, liposarcoma

CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO(TM) as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study

Tue, 02/03/2015 - 13:11
SEATTLE, Feb. 3, 2015 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group, now part of NRG Oncology, informed CTI BioPharma that an independent Data Mo...
Biopharmaceuticals, Oncology
CTI BioPharma, OPAXIO, ovarian cancer, paclitaxel poliglumex

BioLight Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence with the CellDetect(R) Non-Invasive Test

Mon, 02/02/2015 - 15:40
Plans to Secure CE Mark for a European Launch of the Non-Invasive Test and Submit a Pre-IDE to the U.S. FDA in 2015 TEL-AVIV, Israel, Feb. 2, 2015 -- (Healthcare Sales & Marketing Network) -- BioLight Life Sciences Investments Ltd. (OTC: BLGTY, TASE: B...
Devices, Diagnostics, Oncology
BioLight, CellDetect, bladder cancer

FDA Approves New Dosing Option for CSL Behring's Hizentra(R)

Mon, 02/02/2015 - 15:34
New Label Supports Individualized Therapy Through Greater Dosing Flexibility From Daily to Once Every Two Weeks (Biweekly); Underscores CSL Behring's Commitment to Improving Patients' Lives KING OF PRUSSIA, Pa., Feb. 2, 2015 -- (Healthcare Sales & Marke...
Biopharmaceuticals, FDA
CSL Behring, Hizentra, Immune Globulin, immunodeficiency

Calithera Biosciences Appoints Keith Orford, M.D., Ph.D. to Vice President of Clinical Development

Fri, 01/30/2015 - 15:00
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2015 -- (Healthcare Sales & Marketing Network) -- Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor meta...
Biopharmaceuticals, Oncology, Personnel
Calithera Biosciences

OSTAR Launches First Cellular TeleHealth Blood Pressure System for CHF

Fri, 01/30/2015 - 14:52
Breakthrough Affordable Cellular Blood Pressure Solution for Congestive Heart Failure. VANCOUVER, Wash., Jan. 30, 2015 -- (Healthcare Sales & Marketing Network) -- OSTAR Healthcare Technology, a Washington State Based TeleHealth Solutions company, anno...
Devices, Monitoring, Product Launch
OSTAR Healthcare Technology, OSTAR P201, Cellular TeleHealth

Vomaris and Arthrex announce exclusive global distribution agreement for Procellera(R) Technology

Fri, 01/30/2015 - 14:43
TEMPE, Ariz., Jan. 30, 2015 -- (Healthcare Sales & Marketing Network) -- Vomaris Innovations, Inc., an electroceutical company specializing in microcurrent-generating solutions for the wound care market and beyond, announced today that it has entered into...
Devices, Wound Care, Orthopaedic, Distribution
Vomaris Innovations, Arthrex, Procellera, Antimicrobial Wound Dressing

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong